Von willebrand factor human
Voncento (von willebrand factor human) is an unknown pharmaceutical. Von willebrand factor human was first approved as Voncento on 2013-08-12. It has been approved in Europe to treat hemophilia a and von willebrand diseases.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| von willebrand factor/coagulation factor viii complex (human) | Biologic Licensing Application | 2010-08-20 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
108 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | 2 | 6 | 15 | 4 | 21 | 47 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 3 | 3 | 7 | 3 | 9 | 24 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | 3 | 1 | 3 | 8 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | — | — | 1 | 5 | 7 |
| Hemostatic disorders | D020141 | — | — | 1 | — | — | 1 | 5 | 7 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | 1 | — | 1 |
| Blood platelet disorders | D001791 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | 1 | 2 | — | — | 3 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 1 | — | 2 | 3 |
| Postpartum hemorrhage | D006473 | — | O72 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombotic thrombocytopenic purpura | D011697 | — | M31.19 | — | 3 | — | — | 1 | 4 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | 3 | — | — | 1 | 4 |
| Thrombocytopenic purpura | D011696 | — | — | — | 2 | — | — | 1 | 3 |
| Type 2 von willebrand disease | D056728 | Orphanet_166081 | D68.02 | — | 1 | — | — | 2 | 3 |
| Embolism | D004617 | — | — | — | 1 | — | — | — | 1 |
| Thromboembolism | D013923 | HP_0001907 | — | — | 1 | — | — | — | 1 |
| Carotid stenosis | D016893 | — | — | — | 1 | — | — | — | 1 |
| Intracranial embolism | D020766 | EFO_1000991 | I66 | — | 1 | — | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | — | 1 |
| Thrombotic microangiopathies | D057049 | — | M31.1 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 3 von willebrand disease | D056729 | Orphanet_166096 | D68.03 | 1 | — | — | — | 2 | 3 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coagulation protein disorders | D020147 | — | — | — | — | — | — | 3 | 3 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 3 | 3 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | — | — | — | 3 | 3 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | — | — | 3 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 3 | 3 |
| Aortic valve stenosis | D001024 | HP_0001650 | — | — | — | — | — | 3 | 3 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 2 | 2 |
| Fibrosis | D005355 | — | — | — | — | — | — | 2 | 2 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | — | 2 | 2 |
| Aortic valve insufficiency | D001022 | EFO_0007148 | — | — | — | — | — | 2 | 2 |
Show 56 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Von willebrand factor human |
| INN | — |
| Description | Voncento (von willebrand factor human) is an unknown pharmaceutical. Von willebrand factor human was first approved as Voncento on 2013-08-12. It has been approved in Europe to treat hemophilia a and von willebrand diseases. |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298126 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 46,020 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,085 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use